Abemaciclib in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node positive early breast cancer at high risk of recurrence.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||11/04/2022|
|Rapid review completed||06/05/2022|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of abemaciclib compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||26/05/2022|
|Pre-submission consultation with Applicant||26/07/2022|
|Current Status||Awaiting HTA submission from Applicant|